Mesocaine (Lidocaine Hydrochloride)

Lidocaine blocks voltage‑gated sodium channels on nerve membranes, preventing sodium influx that is essential for depolarisation. By inhibiting the generation and propagation of action potentials, it creates a reversible loss of sensation in the area where it is applied, allowing clinicians to control the depth and duration of anesthesia.

The dose of Mesocaine is determined by the prescribing clinician based on the specific procedure, patient characteristics, and route of administration. Dosage may vary widely, and the prescriber will calculate the appropriate amount to achieve effective anesthesia while maintaining safety.

Safety data for lidocaine during pregnancy and lactation are limited. Use is generally reserved for situations where the therapeutic benefit justifies any potential risk to the fetus or infant. Clinicians should evaluate each case individually and discuss possible risks with the patient.

To order Mesocaine, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and the necessary import documentation.

The primary alternative to lidocaine is bupivacaine, another amide‑type local anesthetic. Bupivacaine typically provides a longer duration of action but carries a higher risk of cardiotoxicity at comparable plasma levels. Lidocaine offers a faster onset and a more favourable safety profile for short procedures, making it the preferred choice for many clinicians.

Mesocaine should be stored at room temperature, below 25 °C, in its original packaging. Protect the product from direct sunlight, moisture and extreme temperature fluctuations. Before use, inspect the solution for particulate matter or discoloration and discard if any abnormalities are observed.

Mesocaine is administered by a qualified healthcare professional via infiltration into the target tissue, epidural injection for regional block, or intravenous infusion for systemic analgesia. The route, volume and concentration are selected according to the clinical indication and patient response.

The most serious adverse events associated with lidocaine include seizures, severe cardiac arrhythmias or conduction block, methemoglobinemia, anaphylactic reactions and respiratory depression. Prompt recognition and supportive management are essential if any of these rare but life‑threatening complications occur.

Mesocaine should be avoided in patients with known hypersensitivity to amide‑type local anesthetics, those with severe cardiac conduction disorders, uncontrolled epilepsy, or significant hepatic impairment without dose adjustment. Caution is also advised in pregnant or lactating women when the benefit does not clearly outweigh potential risks.